Overview

* Anebulo fiscal Q1 net loss remains at $2.2 mln, consistent with last year

* Operating expenses for fiscal Q1 decreased slightly to $2.3 mln

* Company advances selonabant for pediatric cannabis toxicity with NIDA grant support

Outlook

* Anebulo expects FDA collaboration for pediatric cannabis toxicity treatment

Result Drivers

* NIDA GRANT SUPPORT - Co received $994,300 from NIDA grant to support selonabant study

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 EPS -$0.05

Q1 Net -$2.20

Income mln

Q1 Basic -$0.05

EPS

Q1 $2.30

Operatin mln

g

Expenses

Analyst Coverage

* The one available analyst rating on the shares is "hold"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)